- Telehealth Visits
- Insurances Accepted
Steven Seyedin, MD
He | Him | HisRadiation Oncology- Telehealth Visits
- Insurances Accepted
Steven Seyedin, MD
He | Him | HisRadiation Oncology- Telehealth Visits
- Insurances Accepted
On this page
About me
Dr. Steven Seyedin is a radiation oncologist who cares for patients with genitourinary cancers (those of the reproductive and urinary systems). His treatment expertise includes prostate, kidney, bladder and testicular cancer.
His research focuses on integrating advanced technologies, such as stereotactic body radiation therapy (which allows precise delivery of high radiation doses), with other targeted therapies in order to improve patients' chances of beating genitourinary cancers. He enjoys collaborating with other UCSF researchers to usher new treatments from the laboratory to the clinic and offering his patients clinical trials with cutting-edge treatment. His work has been published in JAMA Oncology, Frontiers in Oncology, and the International Journal of Radiation Oncology, Biology, and Physics.
He earned his medical degree at the David Geffen School of Medicine at UCLA. He completed a residency in radiation oncology at the University of Iowa.
While he is a San Francisco Bay Area native, he has lived in five states over the past 15 years and was thrilled to come back home to provide care to his community. When he isn't in the clinic or at his office conducting research, he can often be found on a tennis court or spending time with his nephews.
Education
Board Certification
- Radiation Oncology, American Board of Radiology
Residency
- Radiation Oncology, University of Iowa Hospitals & Clinics
Internship
- Internal Medicine, University of Illinois at Chicago College of Med
School
- MD, UCLA David Geffen School of Medicine
Academic Title
- Clinical Professor
Care Keywords
Services
- Radiation Oncology
Treatments
- Volumetric Modulated Arc Therapy
- Three-Dimensional Conformal Radiation Therapy
- External Beam Radiation Therapy
- Stereotactic Ablative Radiotherapy
- Intensity-Modulated Radiation Therapy
- Image-Guided Radiation Therapy
- Radiation Therapy Simulation
Locations
Provider Research Listing
Browse clinical trials and publications by this provider
Clinical trials
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialOpens in a new window
Recruiting
Nephrectomy and radiographic progression-free survival time is defined as time from randomization to the date of first radiographic progression, nephrectomy, d...An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.Opens in a new window
Recruiting
Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS) is defined as the time from randomization to first evidence of radiographic...
Publications
Showing 1-6 of 45 reviews
- July 28, 20265 out of 5 Stars
It was easy to communicate with the provider since he was so friendly and caring
- July 21, 20265 out of 5 Stars
Excellent and caring treatment and experience as always.
- June 14, 20265 out of 5 Stars
Everything about my experience at UCSF is like night and day compared to my other providers
- June 13, 20265 out of 5 Stars
Dr. Seyedin provided clear, comprehensive information about the radiation treatment process. He listened and asked questions to understand my thoughts, and to make sure I understood.
- April 30, 20265 out of 5 Stars
Dr. Seyedin is very professional, knowledgeable, and Is a great communicator, he's the BEST!
- April 22, 20265 out of 5 Stars
Very.thorough.
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.